{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:55:24Z","timestamp":1790697324833,"version":"4.1.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.isci.2026.115191","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T16:12:41Z","timestamp":1772295161000},"page":"115191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacogenomic diversity among Arab populations: A systematic review"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4673-6692","authenticated-orcid":false,"given":"Zeina N.","family":"Al-Mahayri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mais N.","family":"Alqasrawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubna Q.","family":"Khasawneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar M.","family":"Altoum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areej S.","family":"Albawa\u2019neh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilas","family":"Dabaghie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassam R.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2026.115191_bib1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41397-024-00326-1","article-title":"A review of real-world evidence on preemptive pharmacogenomic testing for preventing adverse drug reactions: a reality for future health care","volume":"24","author":"Chenchula","year":"2024","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.isci.2026.115191_bib2","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/s41576-022-00572-8","article-title":"Pharmacogenomics: current status and future perspectives","volume":"24","author":"Pirmohamed","year":"2023","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.isci.2026.115191_bib3","article-title":"From pharmacogenetics to pharmaco-omics: Milestones and future directions","volume":"3","author":"Auwerx","year":"2022","journal-title":"HGG Adv."},{"key":"10.1016\/j.isci.2026.115191_bib4","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1002\/cpt.2122","article-title":"Pharmacogenetics at Scale: An Analysis of the UK Biobank","volume":"109","author":"McInnes","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.isci.2026.115191_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.110916","article-title":"Genetic ancestry in population pharmacogenomics unravels distinct geographical patterns related to drug toxicity","volume":"27","author":"Karamperis","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.isci.2026.115191_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1180487","article-title":"Editorial: Pharmacogenomics and ethnicity: Prevalence and clinical significance of pharmacogenomic biomarkers in indigenous and other populations","volume":"14","author":"Patrinos","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.isci.2026.115191_bib7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/bcp.14983","article-title":"Health equality, race and pharmacogenomics","volume":"88","author":"Magavern","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.isci.2026.115191_bib8","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13073-023-01254-8","article-title":"Massive underrepresentation of Arabs in genomic studies of common disease","volume":"15","author":"Bhattacharya","year":"2023","journal-title":"Genome Med."},{"key":"10.1016\/j.isci.2026.115191_bib9","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2174\/0113892002323910240924145310","article-title":"Drug Metabolizing Enzymes: An Exclusive Guide into Latest Research in Pharmaco-genetic Dynamics in Arab Countries","volume":"25","author":"Eitan","year":"2024","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.isci.2026.115191_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2020.144408","article-title":"Pharmacogenomic landscape of VIP genetic variants in Jordanian Arabs and comparison with worldwide populations","volume":"737","author":"AL-Eitan","year":"2020","journal-title":"Gene"},{"key":"10.1016\/j.isci.2026.115191_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-78231-3","article-title":"Variation in 100 relevant pharmacogenes among emiratis with insights from understudied populations","volume":"10","author":"Al-Mahayri","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2026.115191_bib12","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41525-022-00281-5","article-title":"A population study of clinically actionable genetic variation affecting drug response from the Middle East","volume":"7","author":"Jithesh","year":"2022","journal-title":"npj Genom. Med."},{"key":"10.1016\/j.isci.2026.115191_bib13","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2174\/0127724328335492241206075509","article-title":"Pharmacogenetic Variations in Arab Populations: Clinical Implications for Personalized Drug Therapy","volume":"20","author":"Al-Eitan","year":"2025","journal-title":"Curr. Rev. Clin. Exp. Pharmacol."},{"key":"10.1016\/j.isci.2026.115191_bib15","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00228-014-1801-z","article-title":"Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?","volume":"71","author":"Birmingham","year":"2015","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.isci.2026.115191_bib16","doi-asserted-by":"crossref","first-page":"49","DOI":"10.31782\/IJCRR.2021.131921","article-title":"Single Nucleotide Polymorphisms of ATP-Binding Cassette Gene(ABCC3 rs4793665) affect High Dose Methotrexate-Induced Nephrotoxicity in Children with Osteosarcoma","volume":"13","author":"Zakaria","year":"2021","journal-title":"IJCRR"},{"key":"10.1016\/j.isci.2026.115191_bib17","doi-asserted-by":"crossref","first-page":"555","DOI":"10.13005\/bbra\/2661","article-title":"Contribution of Genetic Variants of ABC Transporters (ABCC1 and ABCG2) Genes With the Pathogenesis of Colorectal Cancer","volume":"15","author":"Al-Doghaither","year":"2018","journal-title":"Biosci. Biotechnol. Res. Asia"},{"key":"10.1016\/j.isci.2026.115191_bib18","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/cpt.2557","article-title":"The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms","volume":"111","author":"Cooper-DeHoff","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.isci.2026.115191_bib19","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1002\/cpt.1319","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of RYR1 or CACNA1S Genotypes","volume":"105","author":"Gonsalves","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.isci.2026.115191_bib20","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/s41397-018-0022-8","article-title":"Pharmacogenomic survey of Qatari populations using whole-genome and exome sequences","volume":"18","author":"Sivadas","year":"2018","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.isci.2026.115191_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047614","article-title":"Exome Sequencing of Only Seven Qataris Identifies Potentially Deleterious Variants in the Qatari Population","volume":"7","author":"Rodriguez-Flores","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2026.115191_bib22","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/humu.24278","article-title":"Actionable genomic variants in 6045 participants from the Qatar Genome Program","volume":"42","author":"Elfatih","year":"2021","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.isci.2026.115191_bib23","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/FPC.0000000000000393","article-title":"PharmGKB summary: very important pharmacogene information for CACNA1S","volume":"30","author":"Sangkuhl","year":"2020","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.isci.2026.115191_bib24","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1007\/s12032-013-0782-6","article-title":"Functional polymorphism of CYP2B6 G15631T is associated with hematologic and cytogenetic response in chronic myeloid leukemia patients treated with imatinib","volume":"31","author":"Kassogue","year":"2014","journal-title":"Med. Oncol."},{"key":"10.1016\/j.isci.2026.115191_bib25","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijid.2019.02.025","article-title":"Cytochrome P450 CYP2B6\u22176 distribution among Congolese individuals with HIV, Tuberculosis and Malaria infection","volume":"82","author":"Peko","year":"2019","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.isci.2026.115191_bib26","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s12041-015-0581-2","article-title":"Characterization of drug-metabolizing enzymes CYP2C9, CYP2C19 polymorphisms in Tunisian, Kuwaiti and Bahraini populations","volume":"94","author":"Abdelhedi","year":"2015","journal-title":"J. Genet."},{"key":"10.1016\/j.isci.2026.115191_bib27","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00228-018-2423-7","article-title":"Influence of genetic and non-genetic factors on acenocoumarol maintenance dose requirement in a Tunisian population","volume":"74","author":"Ajmi","year":"2018","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.isci.2026.115191_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0263137","article-title":"Identification of pharmacogenetic variants from large scale next generation sequencing data in the Saudi population","volume":"17","author":"Goljan","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2026.115191_bib29","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41397-023-00300-3","article-title":"Targeted next-generation sequencing of genes involved in Warfarin Pharmacodynamics and pharmacokinetics pathways using the Saudi Warfarin Pharmacogenetic study (SWAP)","volume":"23","author":"Ammari","year":"2023","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.isci.2026.115191_bib30","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.sjbs.2020.10.052","article-title":"Decoding variants in drug-metabolizing enzymes and transporters in solid tumor patients by whole-exome sequencing","volume":"28","author":"Aboul-Soud","year":"2021","journal-title":"Saudi J. Biol. Sci."},{"key":"10.1016\/j.isci.2026.115191_bib31","doi-asserted-by":"crossref","first-page":"578","DOI":"10.3390\/genes9120578","article-title":"Impact of CYP2C9 and VKORC1 Polymorphisms on Warfarin Sensitivity and Responsiveness in Jordanian Cardiovascular Patients during the Initiation Therapy","volume":"9","author":"AL-Eitan","year":"2018","journal-title":"Genes"},{"key":"10.1016\/j.isci.2026.115191_bib32","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jsps.2019.01.011","article-title":"Effects of CYP2C9 and VKORC1 polymorphisms on warfarin sensitivity and responsiveness during the stabilization phase of therapy","volume":"27","author":"Al-Eitan","year":"2019","journal-title":"Saudi Pharm. J."},{"key":"10.1016\/j.isci.2026.115191_bib33","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/clpt.2011.269","article-title":"Decreased Warfarin Clearance with the CYP2C9 R150H (\u22178) Polymorphism","volume":"91","author":"Liu","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.isci.2026.115191_bib34","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/jhg.2012.94","article-title":"Warfarin pharmacogenetics: development of a dosing algorithm for Omani patients","volume":"57","author":"Pathare","year":"2012","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.isci.2026.115191_bib35","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.2217\/pgs-2016-0130","article-title":"Landscape of warfarin and clopidogrel pharmacogenetic variants in Qatari population from whole exome datasets","volume":"17","author":"Sivadas","year":"2016","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.isci.2026.115191_bib36","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.2217\/pgs.09.71","article-title":"CYP2C9\u22178 is prevalent among African\u2013Americans: implications for pharmacogenetic dosing","volume":"10","author":"Scott","year":"2009","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.isci.2026.115191_bib37","article-title":"A study of CYP2C19\u22172, \u22173 and \u22177 in different Sudanese ethnic groups and their response to omeprazole based triple therapy in Khartoum, Sudan 2016-2017","volume":"29","author":"Khalil","year":"2018","journal-title":"Biomed. Res."},{"key":"10.1016\/j.isci.2026.115191_bib38","doi-asserted-by":"crossref","first-page":"179","DOI":"10.5414\/CP201784","article-title":"Factors that contribute to clopidogrel resistance in cardiovascular disease patients: environmental and genetic approach","volume":"51","author":"Al-Azzam","year":"2013","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.isci.2026.115191_bib39","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.4314\/tjpr.v15i12.30","article-title":"Screening for CYP2C19 Gene variants in a healthy Jordanian population","volume":"15","author":"Yasin","year":"2017","journal-title":"Trop. J. Pharm. Res."},{"key":"10.1016\/j.isci.2026.115191_bib40","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2174\/1872312810666151117122841","article-title":"Impact of Cytochrome P450 2C19\u22172 and \u22173 on Clopidogrel Loading Dose in Saudi Patients with Acute Coronary Syndrome","volume":"10","author":"Khalaf","year":"2016","journal-title":"Drug Metab. Lett."},{"key":"10.1016\/j.isci.2026.115191_bib41","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/6425708","article-title":"Role of Four ABC Transporter Genes in Pharmacogenetic Susceptibility to Breast Cancer in Jordanian Patients","volume":"2019","author":"Al-Eitan","year":"2019","journal-title":"J. Oncol."},{"key":"10.1016\/j.isci.2026.115191_bib42","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/jpm10010002","article-title":"Genetic Polymorphisms of Pharmacogenes among the Genetically Isolated Circassian Subpopulation from Jordan","volume":"10","author":"AL-Eitan","year":"2020","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.isci.2026.115191_bib43","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1089\/gtmb.2012.0122","article-title":"Frequency of certain single-nucleotide polymorphisms and duplication of CYP2D6 in the Jordanian population","volume":"16","author":"Zihlif","year":"2012","journal-title":"Genet. Test. Mol. Biomark."},{"key":"10.1016\/j.isci.2026.115191_bib44","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/cpt.1643","article-title":"PharmVar GeneFocus: CYP2D6","volume":"107","author":"Nofziger","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.isci.2026.115191_bib45","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40246-022-00378-z","article-title":"Frequencies of CYP2D6 genetic polymorphisms in Arab populations","volume":"16","author":"Alali","year":"2022","journal-title":"Hum. Genomics"},{"key":"10.1016\/j.isci.2026.115191_bib47","first-page":"53","article-title":"Xenobiotics Metabolizing Enzymes Gene Polymorphism and susceptibility of Hepatocellular Carcinoma in Egyptian Patients with Hepatitis C Virus-induced Cirrhosis","volume":"36","author":"Obada","year":"2016","journal-title":"Bull. Egyp. Soc. Physiol. Sci."},{"key":"10.1016\/j.isci.2026.115191_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.mgene.2021.100926","article-title":"Association of cytochrome P2D6 gene polymorphism with the susceptibility of Egyptian patients to systemic sclerosis disease","volume":"29","author":"Sarhan","year":"2021","journal-title":"Meta Gene"},{"key":"10.1016\/j.isci.2026.115191_bib49","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0304-3835(97)00265-6","article-title":"The CYP2D6 extensive metabolizer genotype is associated with increased risk for bladder cancer","volume":"119","author":"Abdel-Rahman","year":"1997","journal-title":"Cancer Lett."},{"key":"10.1016\/j.isci.2026.115191_bib50","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1365-2710.2006.00763.x","article-title":"CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine","volume":"31","author":"Shams","year":"2006","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.isci.2026.115191_bib51","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00008571-199706000-00003","article-title":"Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians","volume":"7","author":"McLellan","year":"1997","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.isci.2026.115191_bib52","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/01.fpc.0000239974.69464.f2","article-title":"CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure","volume":"17","author":"Sistonen","year":"2007","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.isci.2026.115191_bib53","doi-asserted-by":"crossref","first-page":"434","DOI":"10.6002\/ect.2021.0101","article-title":"Frequency of ABCB1 C3435T and CYP3A5\u22173 Genetic Polymorphisms in the Lebanese Population","volume":"19","author":"Milane","year":"2021","journal-title":"Exp. Clin. Transplant."},{"key":"10.1016\/j.isci.2026.115191_bib54","first-page":"275","article-title":"A systematic review and meta-analysis recite the efficacy of Tacrolimus treatment in renal transplant patients in association with genetic variants of CYP3A5 gene","volume":"11","author":"Chauhan","year":"2023","journal-title":"Am. J. Clin. Exp. Urol."},{"key":"10.1016\/j.isci.2026.115191_bib55","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1111\/bcp.14608","article-title":"Warfarin dosing algorithms: A systematic review","volume":"87","author":"Asiimwe","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.isci.2026.115191_bib56","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41416-024-02754-z","article-title":"DPYD genetic polymorphisms in non-European patients with severe fluoropyrimidine-related toxicity: a systematic review","volume":"131","author":"Chan","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.isci.2026.115191_bib57","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jmoldx.2024.05.015","volume":"26","author":"Pratt","year":"2024","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.isci.2026.115191_bib58","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-29262-z","article-title":"Gender differences in prevalence of hepatitis C virus infection in Egypt: a systematic review and meta-analysis","volume":"13","author":"Abdel-Gawad","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2026.115191_bib59","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/clpt.2013.203","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-\u03b1-based regimens","volume":"95","author":"Muir","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.isci.2026.115191_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.00916","article-title":"ITPA, TPMT, and NUDT15 Genetic Polymorphisms Predict 6-Mercaptopurine Toxicity in Middle Eastern Children With Acute Lymphoblastic Leukemia","volume":"10","author":"Moradveisi","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.isci.2026.115191_bib61","first-page":"1065","article-title":"Genetic study of Thiopurin S-Methyltransferase and nudix hydrolase genes in a sample of Iraqi children","volume":"14","author":"Alani","year":"2020","journal-title":"EurAsia J. BioSci."},{"key":"10.1016\/j.isci.2026.115191_bib63","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/cpt.1304","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update","volume":"105","author":"Relling","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.isci.2026.115191_bib64","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1182\/blood.V122.21.4926.4926","article-title":"Genetic Polymorphisms In Candidate Genes Predict Increased Toxicity With Methotrexate Therapy In Children With Acute Lymphoblastic Leukemia In Lebanon","volume":"122","author":"Zgheib","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.115191_bib65","first-page":"529","article-title":"Effects of Thiopurine Methyltransferase (TPMT) Polymorphism on Red Blood Cells and Plasma Concentration of 6-Mercaptopurine: Clinical Study","volume":"10","author":"Khudair Hassan","year":"2019","journal-title":"J. Glob. Pharma Technol."},{"key":"10.1016\/j.isci.2026.115191_bib66","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2147\/PGPM.S285033","article-title":"The Association Between Azathioprine Genetic Polymorphisms, Clinical Efficacy and Adverse Drug Reactions Among Egyptian Patients with Autoimmune Diseases","volume":"14","author":"Abuelsoud","year":"2021","journal-title":"PGPM"},{"key":"10.1016\/j.isci.2026.115191_bib67","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s11033-012-2174-y","article-title":"Genetic polymorphisms of NQO1, CYP1A1 and TPMT and susceptibility to acute lymphoblastic leukemia in a Tunisian population","volume":"40","author":"Ouerhani","year":"2013","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.isci.2026.115191_bib68","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1200\/OP.21.00624","article-title":"All You Need to Know About UGT1A1 Genetic Testing for Patients Treated With Irinotecan: A Practitioner-Friendly Guide","volume":"18","author":"Karas","year":"2022","journal-title":"JCO Oncol. Pract."},{"key":"10.1016\/j.isci.2026.115191_bib69","first-page":"702","article-title":"Implication of genetic variation at the promoter and exon1 of UGT1A1 in occurrence of cholelithiasis in Tunisia","volume":"70","author":"Chaouch","year":"2012","journal-title":"Ann. Biol. Clin."},{"key":"10.1016\/j.isci.2026.115191_bib70","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/S0006-2952(03)00074-1","article-title":"Frequent co-occurrence of the TATA box mutation associated with Gilbert\u2019s syndrome (UGT1A1\u221728) with other polymorphisms of the UDP-glucuronosyltransferase-1 locus (UGT1A6\u22172 and UGT1A7\u22173) in Caucasians and Egyptians","volume":"65","author":"K\u00f6hle","year":"2003","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.isci.2026.115191_bib71","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1469-1809.2010.00638.x","article-title":"Prevalence of clinically relevant UGT1A alleles and haplotypes in African populations","volume":"75","author":"Horsfall","year":"2011","journal-title":"Ann. Hum. Genet."},{"key":"10.1016\/j.isci.2026.115191_bib72","doi-asserted-by":"crossref","first-page":"372","DOI":"10.5144\/0256-4947.2013.372","article-title":"UGT1A1 promoter polymorphism associated with serum bilirubin level in Saudi patients with sickle cell disease","volume":"33","author":"Hamad","year":"2013","journal-title":"Ann. Saudi Med."},{"key":"10.1016\/j.isci.2026.115191_bib73","doi-asserted-by":"crossref","first-page":"731","DOI":"10.5114\/aoms.2013.37012","article-title":"Distribution of selected gene polymorphisms of UGT1A1 in a Saudi population","volume":"9","author":"Alkharfy","year":"2013","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.isci.2026.115191_bib74","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/FPC.0000000000000024","article-title":"PharmGKB summary: very important pharmacogene information for UGT1A1","volume":"24","author":"Barbarino","year":"2014","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.isci.2026.115191_bib75","doi-asserted-by":"crossref","first-page":"908","DOI":"10.4103\/1319-2442.190782","article-title":"VKORC1 Gene (Vitamin K Epoxide Reductase) Polymorphisms are Associated with Cardiovascular Disease in Chronic Kidney Disease Patients on Hemodialysis","volume":"27","author":"Osman","year":"2016","journal-title":"Saudi J. Kidney Dis. Transpl."},{"key":"10.1016\/j.isci.2026.115191_bib76","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jsps.2019.11.024","article-title":"Association between ABCB1, ABCG2 carrier protein and COX-2 enzyme gene polymorphisms and breast cancer risk in a Turkish population","volume":"28","author":"Zeliha","year":"2020","journal-title":"Saudi Pharm. J."},{"key":"10.1016\/j.isci.2026.115191_bib77","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/ijc.26436","article-title":"A comprehensive study of polymorphisms in the ABCB1, ABCC2, ABCG2, NR1I2 genes and lymphoma risk","volume":"131","author":"Campa","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.isci.2026.115191_bib78","first-page":"157","article-title":"Malignant hyperthermia in a Saudi child","volume":"8","author":"Radwan","year":"1985","journal-title":"Middle East J. Anaesthesiol."},{"key":"10.1016\/j.isci.2026.115191_bib79","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/cpt.3405","article-title":"PharmVar GeneFocus: CYP4F2","volume":"116","author":"Zubiaur","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.isci.2026.115191_bib80","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0192269","article-title":"The genetic heterogeneity of Arab populations as inferred from HLA genes","volume":"13","author":"Hajjej","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2026.115191_bib81","author":"Al-Mahayri"},{"key":"10.1016\/j.isci.2026.115191_bib82","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/bcpt.13779","article-title":"A paradigm shift in pharmacogenomics: From candidate polymorphisms to comprehensive sequencing","volume":"131","author":"Zhou","year":"2022","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.isci.2026.115191_bib84","doi-asserted-by":"crossref","first-page":"6648","DOI":"10.3390\/jcm12206648","article-title":"Epidemiology of Glucose-6-Phosphate Dehydrogenase Deficiency in Arab Countries: Insights from a Systematic Review","volume":"12","author":"Alangari","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.isci.2026.115191_bib85","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226005663?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226005663?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:55:20Z","timestamp":1790693720000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004226005663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":81,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2589004226005663"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2026.115191","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacogenomic diversity among Arab populations: A systematic review","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2026.115191","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"115191"}}